Influence of baseline demographics/disease characteristics on efficacy of an oral selective TYK2 inhibitor, BMS-986165, in patients with moderate to severe plaque psoriasis: Phase 2, randomized, placebo-controlled trial

K Gordon, K Papp, M Gooderman, D Thaci, P Foley, A Morita, S Kundu, R Kisa, A Napoli, S Banerjee
2019 SKIN The Journal of Cutaneous Medicine  
not available.
doi:10.25251/skin.3.supp.14 fatcat:dzhwbkudufedrdfn4ppff2gxs4